Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIO trial in premenopausal HR-positive HER2-negative early breast cancer
ACTRN12623000657628Phase 2Recruiting
- Sponsor
- Breast Cancer Trials
- Start
- Dec 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, durvalumab and paclitaxel in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoint: Pathologic complete response rate. Started Dec 2024; status: recruiting.
02
Drugs
olaparibdurvalumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12623000657628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000657628.